Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies.

Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies.
复制标题

DOI:
10.15252/emmm.201707567
复制
发表时间:
2017-08
影响因子:
11.1
通讯作者:
Seymour LW
Seymour LW
中科院分区:
医学1区
文献类型:
--
作者:
Freedman JD;Hagel J;Scott EM;Psallidas I;Gupta A;Spiers L;Miller P;Kanellakis N;Ashfield R;Fisher KD;Duffy MR;Seymour LW

文献摘要

参考文献

被引文献

相似文献

溶瘤病毒利用癌细胞表型完成其裂解生命周期,释放子代病毒感染附近细胞并重复该过程。我们对溶瘤B组腺病毒EnAdenotucirev(EnAd)进行了修饰,使其表达从感染的肿瘤细胞分泌到微环境中的双特异性单链抗体。这种双特异性T细胞粘附分子(BiTE)与靶细胞上的EpCAM结合,并将它们与T细胞上的CD3交联,导致CD4和CD8 T细胞的聚集和活化。BiTE转录可以由病毒主要晚期启动子控制,限制表达到允许病毒复制的癌细胞。这种方法可以增强EnAd的细胞毒性,并且我们使用原发性胸腔积液和腹膜恶性腹水证明,尽管存在免疫抑制环境,但用表达BiTE的EnAd感染癌细胞导致内源性T细胞活化以杀死内源性肿瘤细胞。通过这种方式,我们将EnAd武装成联合收割机,将直接溶瘤和T细胞介导的杀伤结合起来,产生了一种有效的治疗方法,可以很容易地转移到临床中。
Oncolytic viruses exploit the cancer cell phenotype to complete their lytic life cycle, releasing progeny virus to infect nearby cells and repeat the process. We modified the oncolytic group B adenovirus EnAdenotucirev (EnAd) to express a bispecific single‐chain antibody, secreted from infected tumour cells into the microenvironment. This bispecific T‐cell engager (BiTE) binds to EpCAM on target cells and cross‐links them to CD3 on T cells, leading to clustering and activation of both CD4 and CD8 T cells. BiTE transcription can be controlled by the virus major late promoter, limiting expression to cancer cells that are permissive for virus replication. This approach can potentiate the cytotoxicity of EnAd, and we demonstrate using primary pleural effusions and peritoneal malignant ascites that infection of cancer cells with the BiTE‐expressing EnAd leads to activation of endogenous T cells to kill endogenous tumour cells despite the immunosuppressive environment. In this way, we have armed EnAd to combine both direct oncolysis and T cell‐mediated killing, yielding a potent therapeutic that should be readily transferred into the clinic.
DOI: 10.1016/j.omto.2016.11.003
发表时间: 2017-03-17
期刊: Molecular therapy oncolytics
影响因子: --
作者:
Dyer A;Di Y;Calderon H;Illingworth S;Kueberuwa G;Tedcastle A;Jakeman P;Chia SL;Brown A;Silva MA;Barlow D;Beadle J;Hermiston T;Ferguson DJ;Champion B;Fisher KD;Seymour LW
通讯作者: Seymour LW
DOI: 10.1016/j.molimm.2005.07.034
发表时间: 2006-03-01
影响因子: 3.6
作者:
Brischwein, K;Schlereth, B;Baeuerle, PA
通讯作者: Baeuerle, PA
DOI: 10.1038/nmeth.1318
发表时间: 2009-05-01
期刊: NATURE METHODS
影响因子: 48
作者:
Gibson, Daniel G.;Young, Lei;Smith, Hamilton O.
通讯作者: Smith, Hamilton O.
DOI: 10.1126/science.1158545
发表时间: 2008-08-15
期刊: SCIENCE
影响因子: 56.9
作者:
Bargou, Ralf;Leo, Eugen;Kufer, Peter
通讯作者: Kufer, Peter
DOI: 10.1182/blood-2012-01-400515
发表时间: 2012-06-28
期刊: BLOOD
影响因子: 20.3
作者:
Klinger, Matthias;Brandl, Christian;Kufer, Peter
通讯作者: Kufer, Peter